FRANKLIN LAKES, N.J., Nov. 10, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company today announced a new research collaboration supported by JDRF, the leading global organization funding type 1 diabetes (T1D) research.

The collaboration expands the commitment from JDRF and BD to explore new advancements in therapy options for people with type 1 diabetes. This new, two-year funding commitment from JDRF will enable BD to focus on technology enhancements to support the development of an extended wear insulin infusion set.

While BD has been working to improve new advancements in insulin infusion delivery technologies, this new collaboration with JDRF will enable accelerated research into the biological causes of limited set life, with subsequent concept prototyping and testing. Current insulin infusion sets are only cleared by the FDA and other regulatory authorities for up to three day use. The goal of the collaboration is to address the mechanical-material and biological issues that contribute to limited set lifetime, and design new devices allowing infusion sets to be effective beyond three days, for a majority of patients.

"Insulin infusion therapy has substantial clinical benefits for type 1 diabetes management, yet its potential is limited by an abbreviated three-day infusion set usage life," said Ken Miller, president of Diabetes Care for BD. "Thanks to our latest partnership with JDRF, we can continue to build on the successful innovations BD currently offers in the insulin infusion category. We are extremely excited for this opportunity to advance the science and understanding of insulin delivery."

Vincent Crabtree, Ph.D., director, Research Business Development at JDRF said, "JDRF is pleased to continue our partnership with BD to further reduce the burden of managing infusion sets for people with type 1 diabetes. Living with diabetes is challenging, and JDRF's goal is to provide broad access to innovative therapies, ensuring each person with this disease has access to treatments to enable them to have better outcomes and to lead healthy lives."

Type 1 diabetes is an autoimmune disease in which the body's pancreas stops producing insulin, a hormone needed to turn food into energy. BD's culture of innovation and continuous improvement, combined with its commitment to diabetes education, has enhanced the patient experience to help improve therapy and outcomes for people with diabetes worldwide.

BD will be offering a poster presentation during of the 16(th) Annual Diabetes Technology Meeting being held Nov. 10-12 in Bethesda, Maryland. The presentation entitled, "In Silico Modeling of the Effects of Tissue Microenvironment on Subcutaneous Insulin Absorption," is scheduled for Friday, Nov. 11 at 4 p.m. EST.

About BD
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 40,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit bd.com.

About JDRF
JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested nearly $2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers in more than 100 locations throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF.

    Contacts:

    Matt Coppola             Monique N. Dolecki

    BD Public Relations      BD Investor Relations

    201.847-7370             201.847.5378

    matthew_r_coppola@bd.com monique_dolecki@bd.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bd-collaborates-with-jdrf-to-focus-on-extended-wear-innovations-for-insulin-infusion-delivery-300360355.html

SOURCE BD (Becton, Dickinson and Company)